Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELDORADO: RT Sequence Inversion with Docetaxel in Prostate Cancer
NCT00452556Phase 2Unknown
- Start
- May 2007
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of docetaxel in prostate cancer (PCa) (2 arms). Primary endpoint: Delivery of concurrent, weekly Docetaxel chemotherapy at 3 years. Status: unknown.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00452556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00452556.